Prestin in Human Perilymph, Cerebrospinal Fluid, and Blood as a Biomarker for Hearing Loss

Fuente: Wiley Open Access
Guardado en:
Detalles Bibliográficos
Autores principales: Anselm Joseph Gadenstaetter, Paul Emmerich Krumpoeck, Alice Barbara Auinger, Erdem Yildiz, Aldine Tu, Christian Matula, Christoph Arnoldner, Lukas David Landegger
Formato: Artículo Open Access
Publicado: Wiley 2024
Materias:
Acceso en línea:
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
_version_ 1867003010121465856
author Anselm Joseph Gadenstaetter
Paul Emmerich Krumpoeck
Alice Barbara Auinger
Erdem Yildiz
Aldine Tu
Christian Matula
Christoph Arnoldner
Lukas David Landegger
author_facet Anselm Joseph Gadenstaetter
Paul Emmerich Krumpoeck
Alice Barbara Auinger
Erdem Yildiz
Aldine Tu
Christian Matula
Christoph Arnoldner
Lukas David Landegger
Anselm Joseph Gadenstaetter
Paul Emmerich Krumpoeck
Alice Barbara Auinger
Erdem Yildiz
Aldine Tu
Christian Matula
Christoph Arnoldner
Lukas David Landegger
collection Wiley Open Access
contents Prestin in Human Perilymph, Cerebrospinal Fluid, and Blood as a Biomarker for Hearing Loss Anselm Joseph Gadenstaetter Paul Emmerich Krumpoeck Alice Barbara Auinger Erdem Yildiz Aldine Tu Christian Matula Christoph Arnoldner Lukas David Landegger Otolaryngology–Head and Neck Surgery AbstractObjectiveDetermining the concentration of prestin in human blood, cerebrospinal fluid (CSF), and perilymph (PL), and evaluating its suitability as a clinical biomarker for sensori‐neural hearing loss (SNHL).Study DesignHuman blood, CSF, and PL samples were intraoperatively collected from 42 patients with tumors of the internal auditory canal or with intracochlear tumors undergoing translabyrinthine or middle fossa tumor removal. Prestin concentration was measured using enzyme‐linked immunosorbent assay and linear regression analyses were performed to investigate its associations with audiological as well as vestibular test results.SettingTertiary referral center.ResultsThe median prestin concentration in blood samples of the 42 study participants (26 women, mean ± standard deviation age, 52.7 ± 12.5 years) was 1.32 (interquartile range, IQR, 0.71‐1.99) ng/mL. CSF prestin levels were significantly higher with 4.73 (IQR, 2.45‐14.03) ng/mL (P = .005). With 84.74 (IQR, 38.95‐122.00) ng/mL, PL prestin concentration was significantly higher compared to blood (P = .01) and CSF (P = .03) levels. Linear regression analyses showed significant associations of CSF prestin concentration with preoperative hearing levels (pure‐tone average and word recognition; P = .008, R2 = 0.1894; P = .03, R2 = 0.1857), but no correlations with blood or PL levels.Conclusion and RelevanceThis study's findings highlight the volatile nature of prestin levels and provide the first insights into this potential biomarker's concentrations in body fluids apart from blood. Future investigations should comprehensively assess human prestin levels with different etiologies of SNHL, prestin's natural homeostasis and systemic circulation, and its temporal dynamics after cochlear trauma. Finally, clinically approved detection kits for prestin are urgently required prior to considering a potential translational implementation of this diagnostic technique. 10.1002/ohn.895 http://creativecommons.org/licenses/by/4.0/
doi_str_mv 10.1002/ohn.895
format Artículo Open Access
id wiley_oa_10_1002_ohn_895
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by/4.0/
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Prestin in Human Perilymph, Cerebrospinal Fluid, and Blood as a Biomarker for Hearing Loss
Anselm Joseph Gadenstaetter
Paul Emmerich Krumpoeck
Alice Barbara Auinger
Erdem Yildiz
Aldine Tu
Christian Matula
Christoph Arnoldner
Lukas David Landegger
Otolaryngology–Head and Neck Surgery
Prestin in Human Perilymph, Cerebrospinal Fluid, and Blood as a Biomarker for Hearing Loss Anselm Joseph Gadenstaetter Paul Emmerich Krumpoeck Alice Barbara Auinger Erdem Yildiz Aldine Tu Christian Matula Christoph Arnoldner Lukas David Landegger Otolaryngology–Head and Neck Surgery AbstractObjectiveDetermining the concentration of prestin in human blood, cerebrospinal fluid (CSF), and perilymph (PL), and evaluating its suitability as a clinical biomarker for sensori‐neural hearing loss (SNHL).Study DesignHuman blood, CSF, and PL samples were intraoperatively collected from 42 patients with tumors of the internal auditory canal or with intracochlear tumors undergoing translabyrinthine or middle fossa tumor removal. Prestin concentration was measured using enzyme‐linked immunosorbent assay and linear regression analyses were performed to investigate its associations with audiological as well as vestibular test results.SettingTertiary referral center.ResultsThe median prestin concentration in blood samples of the 42 study participants (26 women, mean ± standard deviation age, 52.7 ± 12.5 years) was 1.32 (interquartile range, IQR, 0.71‐1.99) ng/mL. CSF prestin levels were significantly higher with 4.73 (IQR, 2.45‐14.03) ng/mL (P = .005). With 84.74 (IQR, 38.95‐122.00) ng/mL, PL prestin concentration was significantly higher compared to blood (P = .01) and CSF (P = .03) levels. Linear regression analyses showed significant associations of CSF prestin concentration with preoperative hearing levels (pure‐tone average and word recognition; P = .008, R2 = 0.1894; P = .03, R2 = 0.1857), but no correlations with blood or PL levels.Conclusion and RelevanceThis study's findings highlight the volatile nature of prestin levels and provide the first insights into this potential biomarker's concentrations in body fluids apart from blood. Future investigations should comprehensively assess human prestin levels with different etiologies of SNHL, prestin's natural homeostasis and systemic circulation, and its temporal dynamics after cochlear trauma. Finally, clinically approved detection kits for prestin are urgently required prior to considering a potential translational implementation of this diagnostic technique. 10.1002/ohn.895 http://creativecommons.org/licenses/by/4.0/
title Prestin in Human Perilymph, Cerebrospinal Fluid, and Blood as a Biomarker for Hearing Loss
topic Otolaryngology–Head and Neck Surgery
url https://aao-hnsfjournals.onlinelibrary.wiley.com/doi/10.1002/ohn.895